What does ET stand for?

Essential Thrombocythemia (overproduction of platelets)

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Entomofauna of Turkey Environmental Technology Ephemeris Time Epstein Technique (oral history) Equal Temperament (musical tuning system) Equitemperature Equivalent Training Ersatzteil (German: spare part) Escape Tone (music) Esotropia (form of strabismus)		Essential Tremor EtherTalk Ethiopia Ethiopian Airlines Enterprise (IATA airline code) Ethyl Group (Ch3ch2) Evaluation Team Evan Turner (basketball player) Evapotranspiration Event Timer Event Tree

Samples in periodicals archive:

The main area of focus for the JAK2 program has been the development of orally available JAK2 inhibitors to treat myeloproliferative disorders, which include myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET).

CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL

Spurious serum hyperkalemia in essential thrombocythemia.

Extreme hyperkalemia

The three main MPNs are polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF).

Incyte Announces Major Collaboration and License Agreement for Two ...

Below is a summary of recent developments for our most advanced product candidates: Janus Kinase (JAK) Inhibitor Program INCB18424: (oral formulation) Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) * Resubmitted the Special Protocol Assessment to the U.

Incyte Reports First Quarter 2009 Financial Results and Provides ...

Tuesday, April 21, 8:00 AM -12:00 PM Hall B-F, Denver Convention Center Session Title: Kinase Inhibitors 3 Poster Section: 36 Poster Board Number: 1 [TABLE OMITTED] A specific JAK2 mutation has been observed in about 95% of patients with the myeloproliferative disorder polycythemia vera (PV), and 50% of those with both essential thrombocythemia (ET) and primary myelofibrosis (PMF).

Onconova Therapeutics Announces Presentation of Nonclinical Data on ...

Janus Kinase (JAK) Inhibitor Program INCB18424: Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (oral formulation) * Submitted a Special Protocol Assessment for approval in MF in December.

Incyte Reports Fourth Quarter and Year-End 2008 Financial Results; ...

These programs include: * Janus kinase (JAK) inhibitor program for: - myelofibrosis (MF), - polycythemia vera (PV) & essential thrombocythemia (ET), - rheumatoid arthritis (RA) and - psoriasis * 11beta-HSD1 (HSD1) inhibitor program for type 2 diabetes * Sheddase inhibitor program for breast cancer Paul Friedman, M.

Incyte to Announce 2009 Objectives at JPMorgan Healthcare Conference; ...

The most advanced JAK2 inhibitors are also being evaluated in phase II trials for myelofibrosis, polycythemia vera and essential thrombocythemia.

Research and Markets: A Competitor Analysis for Janus Kinase (JAK) ...